Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis

European Journal of Pharmacology

Volumn 645, Issue 1-3, 2010, Pages 171-176

  Yamashita, Hirotaka ^a   Ito, Tomokazu ^a   Kato, Hideo ^a   Asai, Shusei ^a   Tanaka, Hiroyuki ^a   Nagai, Hiroichi ^a   Inagaki, Naoki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

2,4 Dinitrofluorobenzene; Calcineurin inhibitor; Cyclosporine A; Scratching behavior; Tacrolimus

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; CYCLOSPORIN A; DEXAMETHASONE; DIPHENHYDRAMINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 31; INTERLEUKIN 4; MESSENGER RNA; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; BLOOD VESSEL PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EAR DISEASE; ELECTRIC CURRENT; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCRATCHING;

ANIMALS; ANTIPRURITICS; BEHAVIOR, ANIMAL; CALCINEURIN; CAPILLARY PERMEABILITY; CYCLOSPORINE; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED BALB C; PASSIVE CUTANEOUS ANAPHYLAXIS; PRURITUS; TACROLIMUS;

EID: 77956185665     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.031     Document Type: Article

References (30)

1. Avramoff A., Laor A., Kitzes-Cohen R., Farin D., Domb A.J. Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations. Int. J. Clin. Pharmacol. Ther. 2007, 45:126-132.
2. Boguniewicz M., Fiedler V.C., Raimer S., Lawrence I.D., Leung D.Y., Hanifin J.M. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J. Allergy Clin. Immunol. 1998, 102:637-644.
3. Caelles C., Gonzlez-Sancho J.M., Muñoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 1997, 11:3351-3364.
4. Eisen H.N., Carsten M.E., Belman S. Studies of hypersensitivity to low molecular weight substances. III. The 2, 4-dinitrophenyl group as a determinant in the preciptin reaction. J. Immunol. 1954, 73:296-308.
5. Frei U. Overview of the clinical experience with neural in transplantation. Transplant. Proc. 1999, 31:1669-1674.
6. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl Acad. Sci. USA 1992, 89:3686-3690.
7. Furue M., Furukawa F., Hide M., Takehara K. Guidelines for therapy for atopic dermatitis. Jpn. J. Dermatol. 2004, B114:135-142.
8. Ho S., Clipstone N., Timmermann L., Northrop J., Graef I., Fiorentino D., Nourse J., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996, 80:S40-S45.
9. Inagaki N., Goto S., Nagai H., Koda A. Mouse ear PCA as a model for evaluating antianaphylactic agents. Int. Arch. Allergy Appl. Immunol. 1984, 74:91-92.
10. Inagaki N., Igeta K., Kim J.F., Nagao M., Shiraishi N., Nakamura N., Nagai H. Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur. J. Pharmacol. 2002, 448:175-183.
11. Inagaki N., Igeta K., Shiraishi N., Kim J.F., Nagao M., Nakamura N., Nagai H. Evaluation and characterization of mouse scratching behavior by a new apparatus, MicroAct. Skin Pharmacol. Appl. Skin Physiol. 2003, 16:165-175.
12. Inagaki N., Shiraishi N., Igeta K., Itoh T., Chikumoto T., Nagao M., Kim J.F., Nagai H. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. Eur. J. Pharmacol. 2006, 546:189-196.
13. Inagaki N., Shiraishi N., Igeta T., Nagao M., Kim J.F., Chikumoto T., Itoh T., Tanaka H., Nagai H. Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur. J. Pharmacol. 2010, 626(2-3):283-289.
14. Jacobs M.D., Harrison S.C. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998, 95:749-758.
15. Jain J., Valge-Archer V.E., Sinskey A.J., Rao A. The AP-1 site at -150bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter. J. Exp. Med. 1992, 175:853-862.
16. Kawashima M., Harada S., Tamaki K., Nakagawa H., Shimada S., Ishibashi Y. A safety study of FK506 ointment in patients with atopic dermatitis. J. Clin. Ther. Med. 1997, 13:1483-1492.
17. Klein P.A., Clark R.A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 1999, 135:1522-1525.
18. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
19. Nagai H., Matsuo A., Hiyama H., Inagaki N., Kawada K. Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten. J. Allergy Clin. Immunol. 1997, 100:S39-S44.
20. Okamoto S., Mukaida N., Yasumoto K., Rice N., Ishikawa Y., Horiguchi H., Murakami S., Matsushima K. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J. Biol. Chem. 1994, 269:8582-8589.
21. Piñeyro-López A., Piñeyro-Garza E., Torres-Alanís O., Reyes-Araiza R., Gómez-Silva M., Waksman N., E Salazar-Leal M., Luján-Rangel R. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers. Clin. Ther. 2007, 29:2049-2054.
22. Pritchard D.I. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov. Today 2005, 10:688-691.
23. Ruzicka T., Bieber T., Schöf E., Rubins A., Dobozy A., Bos J.D., Jablonska S., Ahmed I., Thestrup-Pedersen K., Daniel F., Finzi A., Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J. Med. 1997, 337:816-821.
24. Sakurai T., Inagaki N., Nagai H. The effect of anti-tumor necrosis factor (TNF)-alpha monoclonal antibody on allergic cutaneous late phase reaction in mice. Life Sci. 1994, 54:PL291-PL295.
25. Sasakawa Y., Sakuma S., Higashi Y., Sasakawa T., Amaya T., Goto T. FK506 suppresses neutrophil chemoattractant production by peripheral blood mononuclear cells. Eur. J. Pharmacol. 2000, 403:281-288.
26. Sonkoly E., Muller A., Lauerma A.I., Pivarcsi A., Soto H., Kemeny L., Alenius H., Dieu-Nosjean M.C., Meller S., Rieker J., Steinhoff M., Hoffmann T.K., Ruzicka T., Zlotnik A., Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 2006, 117(2):411-417.
27. Wahlgren C.F. Itch and atopic dermatitis: an overview. J. Dermatol. 1999, 26:770-779.
28. Wahlgren C.F., Scheynius A., Häermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm. Venereol. (Stockh.) 1990, 70:323-329.
29. Yamashita H., Michibata Y., Mizukami H., Ogihara Y., Morita A., Nose M. Dermal mast cells play a central role in the incidence of scratching behavior in mice induced by multiple application of the hapten, 2,4,6-trinitrochlorobenzene. Exp. Dermatol. 2005, 14:438-444.
30. Yamashita H., Tasaki D., Makino T., Matsuoka K., Nose M., Inagaki N., Mizukami H. The role of IgE and repeated challenge in the induction of persistent increases in scratching behavior in a mouse model of allergic dermatitis. Eur. J. Pharmacol. 2009, 605:153-157.